Robeco Institutional Asset Management B.V. Acquires 22,751 Shares of United Therapeutics Corporation $UTHR

Key Points

• Robeco Institutional Asset Management B.V. increased its stake in United Therapeutics (UTHR) by 25% in Q4, buying 22,751 shares to own 113,850 shares worth about $55.47 million (≈0.26% of the company).
• Significant insider selling: COO Michael Benkowitz sold 22,500 shares for ~$10.68 million and CFO James Edgemond sold 10,000 shares for ~$5.27 million, with insiders offloading 374,270 shares (~$193.65 million) in the past 90 days; insiders now own 10.30% of the stock.
• Fundamentals and analyst view: United Therapeutics reported an EPS beat ($7.70 vs. $6.78) and 7.4% revenue growth (Q), while analysts rate the stock a "Moderate Buy" on average with a $601.50 price target and several recent target upgrades.

Robeco Institutional Asset Management B.V. grew its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 113,850 shares of the biotechnology company's stock after purchasing an additional 22,751 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.26% of United Therapeutics worth $55,473,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. WealthCollab LLC raised its holdings in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Wilmington Savings Fund Society FSB raised its holdings in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock valued at $37,000 after purchasing an additional 49 shares in the last quarter. Abich Financial Wealth Management LLC bought a new position in shares of United Therapeutics during the 3rd quarter valued at $44,000. Finally, Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 85 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Activity

In other news, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the business's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 374,270 shares of company stock worth $193,646,365. Insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 1.0%

Shares of UTHR stock opened at $577.63 on Tuesday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $607.89. The firm has a market cap of $25.32 billion, a PE ratio of 20.70, a price-to-earnings-growth ratio of 1.65 and a beta of 0.75. The stock has a 50 day moving average of $518.73 and a 200-day moving average of $486.05.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts' consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the company earned $6.19 earnings per share. The company's quarterly revenue was up 7.4% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Raymond James Financial assumed coverage on shares of United Therapeutics in a report on Friday. They set an "outperform" rating and a $700.00 price target on the stock. Bank of America lifted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a report on Tuesday, March 31st. TD Cowen lifted their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a "buy" rating in a report on Monday, March 30th. Jefferies Financial Group reiterated a "buy" rating on shares of United Therapeutics in a report on Monday, March 2nd. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Ten investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $601.50.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.